SOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug Development
February 13 2023 - 9:00AM
Business Wire
The expanded partnership aims to leverage the
global SOPHiA DDM™ platform and multimodal algorithmic capabilities
to lead a new era of precision oncology by improving early patient
identification and diagnosis, optimizing clinical development, and
accelerating adoption of innovative medications along the care
pathway
SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a leading
cloud-native global data-sharing network and health analytics
platform, is partnering with AstraZeneca (LSE/STO/Nasdaq: AZN) to
apply their multimodal technology and expertise to the
biopharmaceutical company’s oncology portfolio. The multimodal
approach will go beyond a single data modality, combining radiomics
analysis of medical imaging data, molecular data, digital
pathology, clinical and biologic data for a more comprehensive
assessment of multimodal signatures leveraging proprietary AI and
machine learning technology. Together, the companies will examine
ways to accelerate clinical trials, support evidence generation for
market access, and improve clinical decision-making, helping
clinicians to select the best possible treatments.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230213005096/en/
Multimodality will allow for the
integration of clinical data in AZ’s trials with health system
datasets on advanced molecular diagnostics, radiological and
histological imaging and codified clinical data. (Photo: Business
Wire)
SOPHiA GENETICS is able to support this vision in practice
today. In parallel, SOPHiA GENETICS launched its own real-world
DEEP-Lung-IV clinical study to leverage its multimodal machine
learning-powered analytics capabilities to identify multimodal
predictive signatures of response to immunotherapy for patients
with advanced lung cancer.
“AstraZeneca is a global leader in innovative oncology
therapeutics and has built one of the most diverse and robust
oncology portfolios and R&D pipelines in the industry. Building
on our existing partnership with AstraZeneca, notably to expand
access to HRD testing, we are incredibly excited to deepen our
collaboration to multimodal approaches that will further enable
their precision oncology capabilities,” said Peter Casasanto,
Chief BioPharma Officer of SOPHiA GENETICS.
“We see AstraZeneca as a visionary partner willing to invest in
the next generation of data sciences and technology capabilities at
scale to usher in a new area of data-driven medicine. We are
incredibly excited to further integrate science and technology in
our joint pursuit of transformative impact on patient outcomes,”
said Dr. Philippe Menu, Chief Medical Officer SOPHiA
GENETICS.
“Multimodality aims to harness the power of advanced AI and
machine learning models by integrating multiple data modalities to
obtain key insights which inform prognosis and response to therapy
at the individual patient level. This approach is synergistic with
AstraZeneca’s focus on developing personalized cancer treatment and
has the potential to elevate precision oncology, currently driven
by genomic-based biomarkers, into a truly multimodal connected
health ecosystem,” said Greg Rossi, Senior Vice President,
Oncology Europe & Canada, AstraZeneca.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated
to establishing the practice of data-driven medicine as the
standard of care and for life sciences research. It is the creator
of the SOPHiA DDM™ Platform, a cloud-native platform capable of
analyzing data and generating insights from complex multimodal data
sets and different diagnostic modalities. The SOPHiA DDM™ Platform
and related solutions, products and services are currently used by
a broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook, and Instagram.
Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for
use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management’s beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230213005096/en/
Media Contact: Nick Puleo
npuleo@comsint.com
Investor Contact: Katherine Bailon
IR@sophigenetics.com
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From May 2024 to Jun 2024
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jun 2023 to Jun 2024